Effect of Non-Delineated Normal Volumes in IMRT Treatment for Left Breast Cancer: A Treatment Planning Study

Tamer Dawod¹, Sabbah I. Hammoury²*, Mostafa Elnaggar³, Mustafa Kamal⁴

¹Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
²Medical Physics Department, Alexandria Ayadi Almostakbl Oncology Center (AAAOCT), Alexandria, Egypt
³Department of Cancer Management and Research Medical Research Institute, Alexandria University, Alexandria, Egypt
⁴Metal Physics Lab, Physics Department, Faculty of Science, Mansoura University, Mansoura, Egypt

Email: tamedawod@gmail.com, sabbah_ibrahiem@yahoo.com, elnaggarmost@yahoo.co.uk, kamalmustafa144@gmail.com

Received 23 December 2014; accepted 10 January 2015; published 16 January 2015

Copyright © 2015 by authors and Scientific Research Publishing Inc.
This work is licensed under the Creative Commons Attribution International License (CC BY).
http://creativecommons.org/licenses/by/4.0/

Abstract

Introduction: Intensity Modulated Radiation Therapy (IMRT) planning dose calculation process depends on IMRT dose constraints. So, if there was any structure along the treatment beam path not delineated, it would not be taken into account during that calculation process. During IMRT routine practical work, it is noticed that there are some non-delineated normal tissue volumes that received un-aimed dose. Aim: The purpose of this study was to study the effect of unusually delineated normal volumes in IMRT treatment for left sided breast cancer. Method: Ten left sided breast cancer patients were planned with IMRT inverse planning system. The unusually delineated normal volumes were delineated and taken into account in IMRT dose constraints as an Organ at Risk. Doses received by that volume were compared in the two methods quantitatively from Dose Volume Histograms (DVHs) and qualitatively from (axial cuts). Results: The results showed that doses received by the unusually delineated volume when they were delineated and taken into account in IMRT dose constraints were significantly higher than when they were not. Conclusions: The results showed that for IMRT planning technique used for treating left-sided breast cancer, all of the normal tissues/structures that are closed to the treatment targets must be delineated and taken into account in the IMRT planning dose constraints.

Keywords

Radiotherapy, IMRT, Linear Accelerator, Treatment Planning System TPS, NTIAV

*Corresponding author.

1. Introduction

Conformal radiation therapy (CRT) techniques aim to achieve a high-dose region which conforms as closely as possible to the target volume, thereby enabling both the sparing of normal tissues and radiation dose-escalation [1]-[3].

IMRT involves adjusting the beam-intensity to permit even more conformal dose distributions. In IMRT, the intensity of radiation exposure in one portion of the field is modified depending on whether tumor or normal tissue is present in the beam pathway. To do this, IMRT divides the beam into multiple beamlets. When the beamlet hits normal tissues, the intensity is lowered, and when the beamlet hits tumor, the intensity is higher. The changing of beam intensity is computer controlled. So, delineation of both clinical target volumes and organs at risk is very important when in IMRT in order to achieve its required results [4]-[6].

The IMRT planning dose calculation process depends on IMRT dose constraints. So, if there was any structure along the treatment beam path not delineated, it would not be taken into account during that calculation process.

In general IMRT practical work for several types of tumor cancer (i.e. prostate cancer, head and neck cancer, breast cancer), it is noticed that there are some non-delineated normal tissue volumes that received un-aimed dose [7] [8]. For breast cancer (as the aim of the work), these volumes may include (in some cases), a part of the stomach and/or a part of the liver and sometimes other normal tissues that come with the lower part of the left breast and with the upper part of the left lung. All or some of these volumes are not usually delineated or not taken into account in the IMRT planning dose constraints. These volumes can receive unwanted doses and can be covered by isodose lines of high values (i.e. the 70%, 80%, 85%, 90% and 95% isodose lines) because that the IMRT inverse planning doesn’t take it into consideration during its dose calculation process.

2. Materials and Methods

2.1. Acquisition and Simulation

Ten left-sided breast cancer patients underwent a Computed Tomography (CT) scan with 2 mm slice thickness. All sets of CT cuts were transferred to Focal system. Tumor volumes such as gross target volume (GTV), clinical target volume (CTV), and planning target volume (PTV) [9] as well as Organs at Risk (OARs) had been delineated by the physician on each axial slice, then CT slices were transferred to the treatment planning system (TPS).

2.2. Treatment Planning System

Three-dimensional treatment inverse planning system (CMS) XiO software (release 4.64) was used to carry out dose calculation for all patients under study by Super position algorithm.

XiO employs a conjugate gradient algorithm to search for the minimum value of the cost function, which was a member of the gradient descent family of optimization methods, where variables were changed systematically, as opposed to stochastic methods where variables were changed randomly. The beam parameters were adjusted by changing the intensity distribution, which was physically achieved by creating a series of multileaf collimator (MLC) field segments and assigning a monitor unit (MU) weighting to each. The series of field segments that make up a beam were called a leaf sequence. To control this conversion process the acceptable percentage difference between the desired and the actual dose distribution can be specified. Currently a 2% match was specified, and this typically leads to the generation of 10 to 20 segments per field. The minimum segment Monitor Units (MUs) and field size can also be specified.

2.3. Beams Arrangement

The beam arrangement was determined by the size and location of the tumor. Major five fields with equal values of dose were used to plan each patient. IMRT plans were generated using commercial inverse planning software [10] [11]. The beams are spread around the target with equispace and to avoid the opposing fields an odd numbers of the treatment fields were used. IMRT dose constraints for both target and OARs were entered to Xio TPS [12]-[14]. Also some conditions were given to the inverse TPS which were the minimum, goal and maximum radiation doses for the target volume, the power and weight of each structure (Figure 1). Several trials
Figure 1. IMRT dose constraints for both of the treatment target and OARs for treating the left breast cancer patients under the study.

were taken place by Inverse TPS to achieve the IMRT dose constraints and a homogeneous dose distribution [11] [12].

2.4. Evaluation of the Treatment Plans

The treatment plans can be qualitatively and quantitatively evaluated by many tools which are already included into Xio TPS. In our study, we used two main treatment plan evaluation tools; the visual slice-by-slice review of the treatment plans using isodose lines distribution as a qualitative evaluation for the treatment plans which is important to know the location of the hot and cold areas and review dose distribution to both of the clinical target (in our study is the left breast) and OARs (in our study are ipsilateral lung, heart, contralateral breast) and the Dose Volume Histogram (DVH) was generated to evaluate the dose to the different structures in different treatment plans and it can be used as a quantitative evaluation for the treatment plans [15]-[17]. However, DVHs do not provide spatial information such as the location of the high- and low-dose regions (“hot” and “cold” spots) inside the volume of interest (VOI) [18] [19].

2.5. Delineating the Non-Delineated Normal Tissue Volumes in the Plan

That unusually delineated normal volume and additional portion beside it are delineated as a single structure. We called that as (The Non-Taken Into-Account Volume (NTIAV)) and considered it as an OAR so we referred to it by (OAR4) (where the number 4 refers to that that volume is the organ at risk number 4 after the three usually contoured organs at risk (ipsilateral lung, heart, and contralateral breast).

3. Results

3.1. According to a Qualitative Evaluation Tool (the Axial Cuts)

According to the next two axial cuts groups (a) and (b) (Figure 2) for ten patients respectively and as compared in the two methods of being the NTIAV was non-taken into dose constraints account and when it was taken, a large partition of it was covered with some of high value isodose lines like the 90%, 80%, and 70% of the prescribed dose in the case of being it not taken into account as it is shown in Figure 2(a). But the same volume was significantly spared in the case of being it taken into dose constraint account as it is shown in Figure 2(b).

The axial cuts in groups (a) and (b) for patients no.4, 5 and 6, showed a very important reason for that significant difference between the two plans. It is noticed in (a) that isodose lines passed away sparing the left lung but distributed across the NTIAV. This means that the treatment plan didn’t consider with that Non-Taken Into-Account Volume and distributed the dose across it in order to achieve the other given dose constraints before. But in (b), it is noticed that the plan took that volume into its dose calculation considerations so it spared it to be not covered with high isodose values.

High values isodose lines can also cover a portion of the liver, a portion of colon in addition to that one of the
Figure 2. Group (a) and group (b): Showed two axial cuts for every one of ten left sided breast cancer patients showing the difference between isodose lines values that covered the OAR4 (the brown colored volume) as a Non-Taken Into-Account Volume (NTIAV) and as a Taken Into-Account Volume in IMRT treatment planning respectively.

stomach (as it is showed in Figure 2(a) patients no. 7, 8, 9 and 10). These three portions in addition to other covered surrounded normal tissue volume were contained into the NTIAV delineation to be taken into consideration in plan dose calculation process to give those result showed in Figure 2(b) patients no. 7, 8, 9 and 10.

3.2. According to a Quantitative Evaluation tool (the DVHs)

Figures 3(a)-(c): showed the Mean and Standard Deviation (± SD) of minimum, maximum and mean doses received by PTV in Method 1 when OAR2 was taken into consideration in IMRT dose constraints and in Method 2 when it wasn’t, are (43.06 ± 12.6, 43.09 ± 13), (104 ± 4.22, 102.9 ± 3.20) and (92.3 ± 0.69, 91.9 ± 0.84) respectively. It is noticed that the all values are approximately equal which means that there is no significant difference between the two methods with respect to PTV. But for OAR4, there is a very significant difference between the two methods which is shown in Figures 3(d)-(f) where the Mean and ± SD of minimum, maximum and mean doses received by OAR4 in the two methods are (7.75 ± 3.58, 13 ± 5.12), (72.46 ± 12.22, 94.52 ± 2.86) and (28 ± 7.29, 55 ± 6.96) respectively.

Also, in all DVHs (Figure 4(a)), OAR4 (NTIAV) received lower dose in Method 1 than in Method 2 although of being the dose received by PTV not significantly affected in the two methods and Figure 4(b), showed that all OARs also not significantly affected in both two methods.

Also, we noticed that when the NTIAV is delineated but not taken into account in IMRT dose constraints it gave the same dose distribution as when that volume is not delineated (see Figure 5(a), Figure 5(b)). So, the delineation of that volume does not has any effect as long as it is not being taking into consideration in IMRT dose constraints or dose calculation process.
Figure 3. (a), (b) and (c): showed the mean and Standard Deviation of the minimum, maximum and mean doses received by PTV and (d), (e) and (f): showed the mean and SD of the minimum, maximum and mean doses received by OAR2 in the two methods 1 and 2. (Where Method 1: is when OAR2 was taken into consideration in IMRT dose constraints and Method 2: is when it wasn’t.).

4. Discussion
Although of being many studies related to the use of IMRT for treating left breast cancer but we can’t find any previous studies for this point of research.

5. Conclusion
According to all the previous results, we conclude and recommend that when the IMRT planning technique is
used for treating left-sided breast cancer, all of the normal tissues/structures that are close to the treatment targets must be delineated and taken into account in the IMRT planning dose constraints even these volumes weren’t usually considered as OARs like the stomach, liver, colon and any other healthy tissues coming into the radiation beam pathway.

As a future plan, we recommend that this point of research should be checked for all other tumor sites that can be treated using IMRT technique.
Acknowledgements

The author thanks Prof. Dr. Assem Rostom, consultant clinical oncologist, the general manager of Alexandria Ayadi Almostakbl Oncology Centre (AAAOC) for his valuable support and encouragement.

References


T. Dawod et al.


Abbreviations and Acronyms

IMRT: Intensity-Modulated Radiation Therapy  
DVH: Dose Volume Histogram  
NTIAV: Non-Taken Into-Account Volume  
CRT: Conformal Radiation Therapy  
CT: Computed Tomography  
GTV: Gross Target Volume  
CTV: Clinical Target Volume  
PTV: Planning Target Volume  
OAR: Organ at Risk  
TPS: Treatment Planning System  
CMS: Computerized Medical Systems  
XiO: name of three dimensions treatment planning system  
MUs: Monitor Units  
VOI: Volume of Interest
Scientific Research Publishing (SCIRP) is one of the largest Open Access journal publishers. It is currently publishing more than 200 open access, online, peer-reviewed journals covering a wide range of academic disciplines. SCIRP serves the worldwide academic communities and contributes to the progress and application of science with its publication.

Other selected journals from SCIRP are listed as below. Submit your manuscript to us via either submit@scirp.org or Online Submission Portal.